Key Clinical Performance Measures of Selected Bioresorbable Scaffolds.
Key Clinical Performance Measures of Selected Bioresorbable Scaffolds.
| Device (Manufacturer) | Patients Enrolled | Angiographic Follow-up (months post implant) | Late Lumen Loss (mm) | Clinical Follow-up Period (months) | TLF (%) | Scaffold Thrombosis (%) | Ischemia-driven TLR (%) |
|---|---|---|---|---|---|---|---|
| ABSORB GT1 BRS (Abbott) | 2161* | 6 | 0.19±0.18 | 60 | 11.6 | 2.5 | 8.4 |
| DESolve Nx (Elixir Medical) | 122 | 6 | 0.20±0.32 | 60 | 7.4 | 0 | 4.1 |
| ART Pure (Arterial Remodelling Technologies) | 30 | 6 | - | - | - | - | - |
| MeRes 100 (Meril Life Sciences) | 108 | 6 | 0.15±0.23 | 12 | - | 0 | 0.9 |
| FORTITUDE (Amaranth Medical) | 63 | 24 | 0.27±0.37 | 24 | 4.9 | 1.8 | 5.3 |
| APTITUDE (Amaranth Medical) | 60 | 9 | 0.33±0.36 | 24 | 3.4 | 0 | 0 |
| MAGNITUDE (Amaranth Medical) | 70 | 9 | 0.19±0.16 | 9 | 2.9 | 0 | 0 |
| Mirage (Manli) | 35 | 12 | 0.37±0.14 | 12 | 17.2 | 3.4 | 17.2 |
| NeoVas (Lepu Medical Technology) | 1103 | MSCT follow-up | - | 12 | 3.0 | 0.5 | 1.7 |
| Fantom (REVA Medical) | 117 | 6 | 0.25±0.40 | 24 | 4.2 | 0.8 | 2.9 |
| Magmaris (Biotronik) | 1075 | 12 | 0.52±0.39 | 36 | 4.3 | 0.5 | 2.4 |
MSCT, multi-slice computed tomography; TLF, target lesion failure; TLR, target lesion revascularization.
Modified with updated data from Jinnouchi H et al.6 with permission, ©2018 Springer Nature.